National Allergy Strategy
My Health Record resources
Go to website
250k.org.au/
250K
For Teens and Young Adults
Go to website
Nip Allergies in the Bub
Help prevent food allergy
Go to website
Food Allergy Training
Free online courses
Go to website

ASCIA News

  • New Animation - How to Position a Person having Anaphylaxis
    The ASCIA Action Plan for Anaphylaxis includes the following infographics that show the correct and incorrect positioning of a person having anaphylaxis. When a person has anaphylaxis their blood pressure can drop rapidly, which reduces blood flow to the heart. Laying the...
  • New ASCIA Oral Immunotherapy for Food Allergy information
    Oral immunotherapy (OIT) is a potential treatment for food allergy. There are currently several clinical research trials of food allergy OIT and other treatments for food allergy underway in Australia and other countries. At present there is no evidence that OIT it is a...
  • Updated ASCIA COVID-19 resources
    The ASCIA COVID-19 FAQ, Position Statement and Guides have been updated to reference the following summary of the Australian Technical Advisory Group on Immunisation (ATAGI) statement, issued on 8 April 2021 about AstraZeneca COVID-19 vaccine safety concerns: ATAGI notes...
  • New Animation - How to Safely Remove Ticks
    A new animation showing how to safely remove ticks by freezing, not squeezing, is now available on the ASCIA website www.allergy.org.au/patients/insect-allergy-bites-and-stings   To prevent allergic reactions to ticks it is important that ticks are NOT forcibly removed or...
  • PBS listings of Dupixent (dupilumab) for uncontrolled severe asthma (1st April 2021) and severe atopic dermatitis (1st March 2021)
    Dupixent (dupilumab) is now listed on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of patients aged 12 years and older with: Uncontrolled severe asthma from 1st April 2021; and Severe atopic dermatitis who have failed to respond to optimally...
  • Virtual Meetings about COVID-19 Vaccines
    The following two online events are being hosted by the peak professional bodies for allergy and immunology in Australia, New Zealand and Asia and registration is free.   ASI-ASCIA COVID-19 Vaccine Safety Online Fireside Chat on Wednesday 31st March 2021, 6.30-7.30pm AEST...
  • Updated and New ASCIA Information about Evidence-Based Versus Non Evidence-Based Allergy Tests and Treatments
    Allergy is a science based medical speciality which relies on the use of ‘evidence-based’ allergy tests and treatments. This means that there needs to be published evidence that a test or treatment is reliable, based on studies of other patients with similar conditions. Accurate...
  • New and Updated ASCIA COVID-19 Vaccine FAQs
    The following two new ASCIA COVID-19 Vaccination FAQs have been added to www.allergy.org.au/patients/ascia-covid-19-vaccination-faq, in response to questions about the Pfizer and AstraZeneca COVID-19 vaccines. FAQ 3: Does mRNA which is used in the Pfizer vaccine integrate...
ASCIA Member Login

  • Site updated: 13 Apr 2021

ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...

Join our mailing list here...

AIFA: Donate Now
AIFA: Donate Now
Go to website
National Allergy Strategy
National Allergy Strategy
Go to website
ASCIA: WAO Member
ASCIA: WAO Member
Go to website
About ASCIA

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links

About ASCIA

ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditiation

healthdirect

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.